Biotechnology

Learning Objectives

• Define biotechnology and explain its core principles with historical milestones
• Describe the tools used in recombinant DNA technology: restriction enzymes, vectors, DNA ligase, and host cells
• Explain the step-by-step processes of rDNA technology including DNA isolation, PCR, ligation, transformation, and screening
• Analyze the applications of biotechnology in medicine: recombinant therapeutics, gene therapy, and molecular diagnostics
• Evaluate biotechnological applications in agriculture: GM crops, Bt cotton, Golden Rice, and RNAi technology
• Discuss transgenic animals and their uses in research, medicine, and agriculture
• Critically examine the biosafety concerns, ethical issues, and patenting controversies surrounding modern biotechnology

1. Principles of Biotechnology

Definition & History

Biotechnology is defined as the use of living systems, organisms, or their derivatives to develop products or processes for specific applications. According to the European Federation of Biotechnology (EFB), biotechnology is "the integration of natural sciences and organisms, cells, parts thereof, and molecular analogues for products and services."

Core Principles:

• Genetic Engineering: The deliberate modification of an organism's genetic material (DNA/RNA) to alter its phenotype. This involves techniques such as gene insertion, gene deletion, and gene silencing.
• Aseptic Techniques: Maintenance of a sterile environment to enable the growth of only desired microbes or eukaryotic cells in large-scale production processes. This prevents contamination by unwanted microorganisms.

Traditional vs Modern Biotechnology:

• Traditional Biotechnology: Uses naturally occurring microorganisms through fermentation processes. Examples include the production of bread (yeast), cheese (bacteria + rennet), wine/beer (yeast fermentation), curd (Lactobacillus), and vinegar (Acetobacter). These processes rely on natural microbial activity without genetic modification.
• Modern Biotechnology: Involves recombinant DNA technology, gene cloning, and in vitro gene manipulation. It enables precise, targeted genetic changes that were not possible with traditional methods. The key distinction is the ability to isolate, modify, and reintroduce specific genes across species barriers.

Key Historical Milestones:

Year	Milestone	Scientist(s)
1972	First recombinant DNA molecule created	Paul Berg
1973	First transgenic bacteria (rDNA inserted into E. coli)	Cohen & Boyer
1975	Monoclonal antibody production (hybridoma technology)	Köhler & Milstein
1978	Human insulin gene expressed in E. coli	Genentech
1983	First transgenic plant (tobacco with antibiotic resistance)	Herrera-Estrella & Van Montagu
1985	Polymerase Chain Reaction (PCR) invented	Kary Mullis
1990	First human gene therapy for SCID attempted	Anderson, Blaese & Culver
1996	First mammalian clone (Dolly the sheep)	Ian Wilmut & Roslin Institute
2003	Human Genome Project completed	International Consortium
2012	CRISPR-Cas9 gene editing system discovered	Doudna & Charpentier

Genetic Engineering

Genetic engineering refers to the direct manipulation of an organism's genome using biotechnology techniques. It involves:

• Recombinant DNA Technology: Combining DNA molecules from two or more different sources into a single molecule. This is the foundational technique of modern biotechnology.
• Gene Cloning: Creating multiple identical copies of a gene of interest. The gene is inserted into a vector, which is then introduced into a host cell where it replicates.
• Gene Editing: Making precise changes to specific DNA sequences using tools like CRISPR-Cas9, zinc finger nucleases (ZFNs), and TALENs.

Steps of a typical genetic engineering experiment:

1. Identification and isolation of the gene of interest
2. Selection of a suitable vector (plasmid, virus, etc.)
3. Cutting both the vector and target DNA with the same restriction enzyme
4. Ligation of the gene into the vector using DNA ligase
5. Introduction of the recombinant vector into a host cell (transformation)
6. Screening and selection of transformed cells
7. Expression of the introduced gene and purification of the product

Key Techniques

Key biochemical techniques that enabled modern biotechnology:

• DNA Sequencing: Determining the exact order of nucleotides in a DNA molecule. Sanger sequencing (chain termination method) and Next-Generation Sequencing (NGS) technologies.
• Polymerase Chain Reaction (PCR): Amplification of specific DNA sequences from minute quantities of starting material.
• Gel Electrophoresis: Separation of DNA fragments based on size using an electric field applied across an agarose or polyacrylamide gel. DNA (negatively charged) migrates toward the positive electrode (anode).
• Hybridization Techniques: Southern blotting (DNA detection), Northern blotting (RNA detection), and Western blotting (protein detection) using labeled probes.
• DNA Libraries: Genomic libraries (entire genome) and cDNA libraries (expressed genes, made from mRNA using reverse transcriptase).
• Microarrays: High-throughput analysis of gene expression patterns across thousands of genes simultaneously.

2. Tools of Recombinant DNA Technology

Restriction Enzymes

Restriction endonucleases (molecular scissors) are enzymes that cut DNA at specific recognition sequences. They are produced primarily by bacteria as a defense mechanism against bacteriophages (viral DNA). The bacterial DNA is protected from its own restriction enzymes by methylation of the recognition sites.

Mechanism of action:

• Each restriction enzyme recognizes a specific palindromic DNA sequence (read the same forward and backward on complementary strands)
• It cleaves the phosphodiester backbone at specific points within or near the recognition sequence
• Cleavage generates either sticky ends (overhangs with unpaired bases) or blunt ends (flush cuts with no overhangs)
• Sticky ends facilitate easier ligation because complementary overhangs can hydrogen-bond with each other

Nomenclature of Restriction Enzymes

The naming system for restriction enzymes follows a standardized convention proposed by Smith and Nathans (1973):

EcoRI as an example:

• E — First letter of the genus name (Escherichia)
• co — First two letters of the species name (coli)
• R — Strain designation (strain RY13)
• I — Order of discovery (first enzyme isolated from this strain)

Additional examples: HindIII (Haemophilus influenzae Rd strain, third enzyme), BamHI (Bacillus amyloliquefaciens H strain, first enzyme), Sau3AI (Staphylococcus aureus 3A strain, first enzyme), HaeIII (Haemophilus aegyptius, third enzyme).

Types of Restriction Enzymes

Feature	Type I	Type II	Type III
Recognition site	Bipartite, asymmetric (15-20 bp)	Palindromic, symmetric (4-8 bp)	Bipartite, asymmetric (5-7 bp)
Cleavage site	Non-specific, >1000 bp from recognition site	Within or near recognition site	20-30 bp from recognition site
Cofactors	ATP, Mg²⁺, SAM	Mg²⁺ only	ATP, Mg²⁺
Restriction-modification	Multifunctional enzyme (restriction + methylation)	Separate restriction and methylase enzymes	Multifunctional enzyme
Use in rDNA technology	Not useful (non-specific cutting)	Extensively used (specific, predictable cuts)	Limited use
Sticky/blunt ends	No	Yes (sticky or blunt)	Yes
Examples	EcoKI, EcoBI	EcoRI, HindIII, BamHI, SmaI	EcoP15I, HinfIII

Important Type II restriction enzymes for NEET:

Enzyme	Source Organism	Recognition Sequence (5' to 3')	Cut Pattern
EcoRI	E. coli RY13	GAATTC	G/AATTC (sticky)
HindIII	H. influenzae Rd	AAGCTT	A/AGCTT (sticky)
BamHI	B. amyloliquefaciens H	GGATCC	G/GATCC (sticky)
PstI	Providencia stuartii	CTGCAG	CTGCA/G (sticky)
SmaI	Serratia marcescens	CCCGGG	CCC/GGG (blunt)
SalI	Streptomyces albus G	GTCGAC	G/TCGAC (sticky)

Cloning Vectors

Cloning vectors are DNA molecules used to carry foreign genetic material into a host cell for replication and expression. They serve as the molecular vehicles that deliver genes of interest into host organisms.

Essential features of a good cloning vector:

• Origin of Replication (ori): A specific DNA sequence where replication initiates. This allows the vector to replicate autonomously inside the host cell. The copy number of the vector depends on the ori (e.g., pBR322 has ~15-20 copies/cell, while pUC vectors have ~500-700 copies/cell).
• Selectable Marker: Usually an antibiotic resistance gene (e.g., ampicillin resistance ampR, tetracycline resistance tetR, kanamycin resistance kanR). This allows screening of transformed cells by growing them on antibiotic-containing media.
• Multiple Cloning Site (MCS) / Polylinker: A short DNA sequence containing several unique restriction sites. This allows insertion of the foreign gene at a specific location without disrupting essential vector functions.
• Small Size: Smaller vectors are easier to manipulate and transform efficiently. For example, pBR322 is 4361 base pairs; pUC18 is 2686 base pairs.
• High Copy Number: Vectors with high copy numbers yield more DNA per cell, facilitating analysis and downstream applications.

Plasmids

Plasmids are small, circular, extrachromosomal DNA molecules found naturally in bacteria (and some yeasts). They replicate independently of the bacterial chromosome. Key features:

• pBR322: One of the earliest and most widely used cloning vectors. It contains:
  • ori (origin of replication) from pMB1 plasmid
  • ampR (ampicillin resistance) encoded by bla gene (β-lactamase)
  • tetR (tetracycline resistance) encoded by tet gene
  • rop gene that regulates copy number
  • Multiple unique restriction sites within the antibiotic resistance genes
• pUC18/19: Derived from pBR322 but with improvements:
  • Higher copy number (500-700 copies/cell)
  • Extended MCS with more restriction sites
  • lacZ gene fragment for blue-white screening
  • Smaller size (2686 bp)
• Ti Plasmid (Tumor-inducing): Found in Agrobacterium tumefaciens. Used for plant genetic engineering. A segment called T-DNA is transferred to the plant genome. Disarmed Ti plasmids (with tumor-causing genes removed) are used as vectors.

Bacteriophages

Bacteriophages (phages) are viruses that infect bacteria. They are used as vectors for cloning larger DNA fragments:

• λ (Lambda) Phage: Infects E. coli. The genome is ~48.5 kb linear dsDNA.
  • Cloning capacity: up to 23 kb (after replacing non-essential regions)
  • Efficiency: very high (more efficient than plasmids for large inserts)
  • Used for genomic library construction
  • Two types of replacement vectors (λgt series) and insertion vectors (λZAP)
• M13 Phage: A filamentous phage with ssDNA genome (~6.4 kb).
  • Used for DNA sequencing (Sanger method)
  • Produces single-stranded DNA that can be used as template for sequencing
  • Cloning capacity: up to 1.5 kb

BAC and YAC Vectors

BAC (Bacterial Artificial Chromosomes):

• Based on the F-plasmid (fertility factor) of E. coli
• Cloning capacity: 100-300 kb (ideal for large genomic fragments)
• Used extensively in the Human Genome Project for sequencing
• Stable, low copy number (1-2 copies/cell), preventing recombination
• Contains oriS, repE (replication), parA, parB (partitioning for stable inheritance)
• Selectable markers: chloramphenicol resistance (cmR) or kanamycin resistance (kanR)

YAC (Yeast Artificial Chromosomes):

• Linear vectors that function as chromosomes in yeast (Saccharomyces cerevisiae)
• Cloning capacity: 200-2000 kb (the largest among all vector types)
• Contains essential elements:
  • CEN (centromere) — for proper chromosome segregation during cell division
  • TEL (telomeres) at both ends — for chromosome stability
  • ARS (autonomously replicating sequence) — replication origin
  • Selectable markers (usually auxotrophic markers like URA3, TRP1, LEU2)
• Limitations: lower transformation efficiency, chimeric clones (containing DNA from multiple sources), and instability for some inserts

Comparison of Cloning Vectors:

Vector	Host	Insert Size	DNA Form	Applications
Plasmid (pBR322)	E. coli	Up to 10 kb	Circular dsDNA	Gene cloning, protein expression
λ Phage	E. coli	Up to 23 kb	Linear dsDNA	Genomic libraries
Cosmid	E. coli	35-45 kb	Circular dsDNA	Genomic libraries
BAC	E. coli	100-300 kb	Circular dsDNA	Large genomic inserts, HGP
YAC	S. cerevisiae	200-2000 kb	Linear dsDNA	Very large genomic inserts
Retrovirus	Mammalian cells	Up to 8 kb	RNA → dsDNA	Gene therapy
Ti Plasmid	Plants	Up to 30 kb	Circular dsDNA	Plant genetic engineering

DNA Ligase

DNA ligase (molecular glue) is an enzyme that catalyzes the formation of phosphodiester bonds between adjacent DNA fragments, sealing nicks in the DNA backbone. It is essential for joining the insert (gene of interest) with the vector DNA during recombinant DNA construction.

Two types of DNA ligase used in biotechnology:

• E. coli DNA Ligase: Uses NAD⁺ (nicotinamide adenine dinucleotide) as a cofactor. This ligase cannot join blunt-ended DNA fragments efficiently.
• T4 DNA Ligase: Isolated from bacteriophage T4. Uses ATP as a cofactor. This is the most commonly used ligase in rDNA technology because it can ligate both sticky ends and blunt ends. It is more versatile and efficient than E. coli ligase.

Ligation mechanism: The ligase first forms a covalent enzyme-AMP intermediate. The AMP is then transferred to the 5′-phosphate of the DNA, activating it for attack by the 3′-hydroxyl group. This forms a new phosphodiester bond and releases AMP.

Host Cells

The host cell receives the recombinant DNA molecule and expresses the foreign gene. An ideal host cell should be:

• Easy to grow and maintain in the laboratory
• Capable of taking up exogenous DNA (competent)
• Genetically well-characterized
• Able to express the foreign gene efficiently
• Non-pathogenic (safe to handle)

Common host organisms:

• E. coli: The most widely used bacterial host. Fast growth, easy transformation, well-understood genetics. Limitations: cannot perform eukaryotic post-translational modifications (glycosylation, disulfide bond formation).
• Saccharomyces cerevisiae (Baker's yeast): Eukaryotic host capable of some post-translational modifications. Used for Hepatitis B vaccine production (HBsAg).
• CHO (Chinese Hamster Ovary) Cells: Mammalian cells used for producing complex therapeutic proteins (e.g., erythropoietin, monoclonal antibodies). Can perform proper glycosylation.
• Agrobacterium tumefaciens: Used for plant genetic engineering. Transfers T-DNA to plant cells.
• Bacillus subtilis: Gram-positive host used for industrial enzyme production (amylases, proteases). Secretes proteins into the medium, simplifying purification.

Making cells competent for transformation:

• CaCl₂ (Calcium Chloride) Treatment: Cells treated with cold CaCl₂ solution become permeable to DNA. Heat shock at 42°C for 90 seconds increases DNA uptake. Efficiency: ~10⁶-10⁷ transformants per μg DNA.
• Electroporation: Brief electric pulses (field strength ~12.5-15 kV/cm) create transient pores in the cell membrane through which DNA enters. Higher efficiency: ~10⁹-10¹⁰ transformants per μg DNA.
• Microinjection: Direct injection of DNA into the nucleus using a fine glass needle. Used for creating transgenic animals (e.g., mice, zebrafish).
• Biolistics (Gene Gun): DNA-coated gold or tungsten particles are shot into target cells using a high-pressure gun. Commonly used for plant transformation.
• Liposome-Mediated: DNA is encapsulated within liposomes (artificial lipid vesicles) that fuse with the cell membrane, delivering DNA into the cell.

3. Processes of Recombinant DNA Technology

Isolation of Genetic Material

Step 1: Cell Lysis. The first step is to break open cells to release their DNA. Different methods are used depending on the cell type:

• Bacterial cells: Lysozyme (breaks peptidoglycan layer) + SDS (detergent, disrupts cell membrane)
• Plant cells: Cellulose digestion using cellulase, plus pectinase to break down the middle lamella
• Animal cells: Detergent treatment (SDS or Triton X-100) breaks the cell membrane
• Fungal cells: Chitinase or mechanical disruption (glass beads, grinding)

Step 2: Removal of Contaminants.

• Proteins: Removed by digestion with protease (e.g., proteinase K), followed by phenol-chloroform extraction. Proteins are denatured and partition into the organic phase.
• RNA: Removed by treatment with RNase (ribonuclease), which degrades RNA to ribonucleotides.
• Polysaccharides and lipids: Removed by centrifugation and/or extraction with organic solvents.

Step 3: DNA Precipitation and Purification. DNA is precipitated by adding cold ethanol or isopropanol in the presence of monovalent cations (Na⁺, K⁺, or NH₄⁺). DNA forms a white, thread-like precipitate. After washing with 70% ethanol to remove salts, the DNA is resuspended in TE buffer (Tris-EDTA, pH 8.0) or sterile water.

Cutting with Restriction Enzymes

Both the vector (e.g., plasmid pBR322) and the donor DNA (containing the gene of interest) are separately digested with the same restriction enzyme. This creates complementary sticky ends on both molecules.

Setting up a restriction digestion reaction:

• Template DNA: 0.5-1 μg
• Restriction enzyme: 1-10 units
• Reaction buffer (specific to the enzyme, usually supplied with it)
• BSA (bovine serum albumin): sometimes added to stabilize the enzyme
• Incubation: 37°C for 1-2 hours (or as recommended by manufacturer)
• Heat inactivation: 65°C for 20 minutes (varies by enzyme)

Verification: Digested samples are analyzed by agarose gel electrophoresis. The vector linearization and presence of the expected DNA fragments are confirmed by comparing with a DNA ladder (size marker).

Amplification (PCR)

Polymerase Chain Reaction was invented by Kary Mullis in 1985 (Nobel Prize, 1993). PCR allows the rapid amplification of a specific DNA sequence from a complex mixture, producing millions of copies in just a few hours.

Components of a PCR reaction:

• Template DNA: The DNA containing the target sequence to be amplified (1-100 ng)
• Primers: Two short oligonucleotides (18-25 bases) complementary to the 3' ends of the target sequence on opposite strands. They provide a free 3'-OH group for DNA polymerase to extend.
• DNA Polymerase: Taq polymerase (from Thermus aquaticus) is a thermostable enzyme that works optimally at 72°C. It is not denatured by the high temperatures used in the denaturation step.
• dNTPs: Deoxynucleotide triphosphates (dATP, dCTP, dGTP, dTTP) at equimolar concentrations (200 μM each).
• Buffer: Provides optimal pH (8.3-8.8) and ionic conditions. Contains Tris-HCl, KCl, and MgCl₂. Mg²⁺ is an essential cofactor for Taq polymerase.

PCR Thermal Cycling Steps:

Step	Temperature	Duration	Process
Initial Denaturation	94-96°C	2-5 min	Complete separation of double-stranded DNA into single strands
Denaturation	94-96°C	30-60 sec	DNA strands separate
Annealing	50-65°C	30-60 sec	Primers bind to complementary sequences on template
Extension/Elongation	72°C	30 sec-2 min	Taq polymerase extends primers, synthesizing new strands
Final Extension	72°C	5-10 min	Complete unfinished DNA strands

Number of DNA molecules after PCR: After n cycles, the target sequence is amplified to approximately 2n copies. With 30-35 cycles, one can obtain ~10⁹ copies from a single starting molecule.

Types of PCR:

• RT-PCR (Reverse Transcription PCR): Converts RNA to cDNA using reverse transcriptase, then amplifies the cDNA. Used for detecting RNA viruses (SARS-CoV-2, HIV, HCV) and studying gene expression.
• Real-Time PCR (qPCR): Quantifies DNA amplification in real time using fluorescent dyes (SYBR Green) or probes (TaqMan). Allows accurate quantification of starting template.
• Nested PCR: Uses two rounds of PCR with two sets of primers to increase specificity. Reduces non-specific amplification.
• Multiplex PCR: Contains multiple primer pairs to amplify several targets simultaneously in one reaction.
• Touchdown PCR: Annealing temperature is progressively decreased during cycling to improve specificity.
• Colony PCR: Directly screens bacterial colonies for the presence of the desired insert without prior DNA purification.

Applications of PCR:

• Medical Diagnostics: COVID-19 testing (RT-PCR), HIV viral load monitoring, hepatitis B/C detection, tuberculosis diagnosis, genetic disorder screening
• Forensic Science: DNA fingerprinting from crime scene samples (blood stains, hair roots, saliva)
• Research: Gene cloning, DNA sequencing, site-directed mutagenesis, mutation detection
• Archaeology and Anthropology: Ancient DNA (aDNA) analysis from fossils and archaeological remains
• Paternity Testing: Amplification of STR (short tandem repeat) markers for parentage determination
• Genetically Modified Organism (GMO) Detection: Identifying transgenic sequences in food products

Ligation

DNA ligation is the process of joining the target gene and the vector together to form recombinant DNA. The enzyme T4 DNA ligase catalyzes this reaction.

Optimal conditions for ligation:

• Temperature: 16°C overnight or 22°C for 1-2 hours
• Insert:Vector molar ratio: 3:1 (to favor ligation and reduce self-ligation of vector)
• ATP: required cofactor (0.5-1 mM)
• Buffer: contains Tris-HCl (pH 7.5-8.0), MgCl₂, DTT, ATP

Types of ligation reactions:

• Sticky-end ligation: More efficient because complementary overhangs bring the fragments together via hydrogen bonding. The enzyme seals the nicks.
• Blunt-end ligation: Less efficient (requires higher DNA concentrations and more enzyme) because there are no complementary overhangs to hold the fragments together.
• TA Cloning: Uses Taq polymerase's inherent terminal transferase activity (adds an extra adenine (A) to the 3' ends of PCR products). The PCR product (with A-overhangs) is ligated into a linearized vector with T-overhangs.

After ligation, the products include: recombinant plasmids (vector + insert), religated empty vectors (vector without insert), and concatemers (multiple inserts or vectors joined together).

Transformation

Transformation is the process by which a host cell takes up exogenous DNA from its environment. The recombinant DNA molecule (plasmid with the gene of interest) is introduced into suitable host cells.

Methods of transformation:

• Chemical Transformation (CaCl₂ Method):
  • Bacterial cells are treated with ice-cold CaCl₂ solution (0.1 M), making the cell membrane permeable
  • Cells are incubated with the plasmid DNA on ice (30 minutes)
  • Heat shock at 42°C (90 seconds) creates a thermal gradient that facilitates DNA entry
  • Cells are returned to ice immediately
  • Recovery: cells incubated in nutrient broth (LB) at 37°C for 45-60 minutes to allow expression of antibiotic resistance genes
  • Efficiency: 10⁶-10⁷ transformants per μg DNA
• Electroporation:
  • High-voltage electric pulse (12.5-15 kV/cm, 4-5 ms) is applied to a suspension of cells and DNA
  • Creates transient pores in the cell membrane
  • Higher efficiency (10⁹-10¹⁰ transformants per μg DNA) but requires specialized equipment

Screening & Selection

After transformation, the bacterial culture contains three types of cells:

• Non-transformed: Did not take up any plasmid (no antibiotic resistance)
• Transformed (with non-recombinant vector): Took up the empty vector (self-ligated without insert)
• Transformed (with recombinant vector): Took up the vector containing the inserted gene

Screening methods:

• Selectable Marker Screening: Cells are plated on antibiotic-containing agar. Only cells that received the plasmid (with the antibiotic resistance gene) survive. Both non-recombinant and recombinant vectors will grow.
• Insertional Inactivation (Replica Plating): Used with pBR322:
  • The vector has two antibiotic resistance genes: ampR and tetR
  • If the gene is inserted into the tetR gene (e.g., at the BamHI or SalI site), tetR is disrupted
  • Result: cells are ampicillin-resistant but tetracycline-sensitive
  • Colonies are replica-plated on ampicillin and tetracycline plates
  • Colonies that grow on ampicillin but not on tetracycline contain recombinant plasmids
• Blue-White Screening (LacZ Complementation):
  • The vector contains the lacZ' gene (encodes the α-peptide of β-galactosidase)
  • The host strain has the lacZΔM15 deletion (missing the α-peptide)
  • The MCS is located within the lacZ' gene
  • If no insert: lacZ' is intact → α-complementation occurs → functional β-galactosidase → cleaves X-gal (chromogenic substrate) → blue colonies
  • If insert present: lacZ' is disrupted → no β-galactosidase activity → white colonies
  • IPTG is added as an inducer of the lac operon
• Colony PCR: Individual colonies are picked and used directly as templates for PCR using primers that flank the insertion site. The presence and size of the PCR product confirm the insert.
• Restriction Analysis: Plasmid DNA is isolated from selected colonies, digested with restriction enzymes, and analyzed by gel electrophoresis to confirm the presence of the insert.
• DNA Sequencing: The ultimate confirmation method. The insert is sequenced to verify its identity and ensure no mutations were introduced.

4. Applications in Medicine

Recombinant Therapeutics

Recombinant therapeutics are proteins produced by genetically engineered organisms to treat human diseases. They have several advantages over traditional therapeutics: they are human proteins (reduced immunogenicity), can be produced in large quantities, are free from infectious agents, and have consistent quality.

Recombinant Insulin (Humulin)

Insulin is a polypeptide hormone that regulates blood glucose levels. Human insulin consists of 51 amino acids arranged in two chains: the A chain (21 amino acids) and the B chain (30 amino acids), connected by two disulfide bonds (A7-B7, A20-B19) with an additional intrachain disulfide bond in the A chain (A6-A11).

Historical context: Before 1982, diabetic patients were treated with insulin extracted from the pancreases of pigs (porcine insulin) or cows (bovine insulin). These animal insulins differed slightly from human insulin in amino acid sequence (porcine differs by 1 amino acid, bovine by 3), causing allergic reactions in some patients. Additionally, animal sources could not meet the growing demand.

Production of recombinant human insulin (Humulin):

• Eli Lilly (1982): First rDNA therapeutic approved by the FDA
• The human insulin gene was chemically synthesized and inserted into E. coli via a plasmid vector
• The A chain and B chain genes were cloned separately into two different E. coli cultures
• Each chain was expressed as a fusion protein (with β-galactosidase or TrpE protein) to protect the small peptide from degradation
• The fusion protein was purified and cleaved with cyanogen bromide (at methionine residues) to release the insulin chains
• The A and B chains were purified separately, then mixed together under oxidizing conditions to form disulfide bonds
• The correctly folded insulin (with proper disulfide linkages) was purified by chromatography
• Alternative method (Novo Nordisk): Insulin precursor expressed in yeast (Saccharomyces cerevisiae) as a single-chain proinsulin, which is enzymatically cleaved to mature insulin

Modern insulin analogs developed through recombinant technology:

• Lispro (Humalog): Rapid-acting (Lys at B28, Pro at B29 reversed)
• Glargine (Lantus): Long-acting (solubility altered by adding arginine residues)
• Detemir (Levemir): Long-acting (fatty acid chain added for albumin binding)
• Aspart (NovoLog): Rapid-acting (Asp substitution at B28)

Recombinant Growth Hormone

Human Growth Hormone (hGH): A 191-amino acid polypeptide produced by the anterior pituitary. It is essential for normal growth and development. Deficiency leads to dwarfism.

• Pre-recombinant era: hGH was extracted from human cadavers. This was expensive, limited in supply, and carried the risk of viral contamination (Creutzfeldt-Jakob disease from contaminated batches).
• Recombinant hGH (Protropin, Genentech, 1985): The human GH gene was inserted into E. coli. Since hGH is a single-chain protein (unlike insulin's two chains), it could be produced directly without post-purification assembly.
• Advantages: Unlimited supply, free from infectious agents, no ethical concerns associated with cadaver sourcing.

Gene Therapy

Gene therapy is a medical approach that involves correcting defective genes responsible for disease development. The concept is to deliver a functional copy of the gene to cells that carry a mutated, non-functional version.

Approaches to gene therapy:

• Somatic Cell Gene Therapy: Targets somatic (non-reproductive) cells. Changes are not passed to offspring. Currently, all approved gene therapy protocols use this approach.
• Germline Gene Therapy: Targets germ cells (sperm, eggs, or early embryos). Changes are heritable. This is controversial and currently not approved for human use due to ethical concerns.

Delivery methods:

• Ex Vivo Gene Therapy: Cells are removed from the patient, genetically modified in the laboratory, and re-implanted. This allows for better control and safety.
• In Vivo Gene Therapy: The therapeutic gene is delivered directly to cells inside the patient's body, usually via a viral or non-viral vector injected into the bloodstream or target tissue.

Viral Vectors Used in Gene Therapy:

Vector	Genome	Insert Capacity	Advantages	Disadvantages
Retrovirus (MMLV)	ssRNA → dsDNA	~8 kb	Stable integration into host genome; long-term expression	Only infects dividing cells; insertional mutagenesis risk
Adenovirus	dsDNA	~8 kb (up to 36 kb in gutless versions)	Infects dividing and non-dividing cells; high titers	Transient expression (no integration); strong immune response
AAV (Adeno-Associated Virus)	ssDNA	~4.5 kb	Non-pathogenic; infects dividing/non-dividing cells; integrates at specific site (AAVS1 on chr 19)	Small insert capacity; requires helper virus for replication
Lentivirus (HIV-based)	ssRNA → dsDNA	~8 kb	Infects dividing and non-dividing cells; stable integration	Safety concerns (derived from HIV); insertional mutagenesis

Case Study: SCID (Severe Combined Immunodeficiency)

• Disease: Caused by deficiency of adenosine deaminase (ADA), an enzyme essential for purine metabolism. Without ADA, toxic metabolites (deoxyadenosine) accumulate, particularly affecting T lymphocytes → severe immune deficiency.
• First human gene therapy trial (1990): Ashanti DeSilva (4-year-old girl) was the first patient. T lymphocytes were isolated from her blood, transformed with a retrovirus carrying the functional ADA gene, and re-infused. She received multiple treatments over several years and showed significant improvement.
• Current status (2016): Strimvelis (ADA-SCID gene therapy) was approved in Europe. Uses a lentiviral vector to deliver the ADA gene to autologous hematopoietic stem cells. Single treatment leads to sustained correction.

Other gene therapy successes:

• Hemophilia B (2011): AAV vector delivering Factor IX gene to liver cells
• LCA (Leber Congenital Amaurosis, 2017): Luxturna (AAV vector for RPE65 gene) approved by FDA
• Spinal Muscular Atrophy (2019): Zolgensma (AAV9 vector carrying SMN1 gene) approved by FDA
• β-Thalassemia (2019): Zynteglo (lentiviral vector delivering β-globin gene) approved in Europe

Molecular Diagnostics

Biotechnology has revolutionized medical diagnostics by providing highly sensitive and specific methods for detecting pathogens, genetic mutations, and disease biomarkers.

PCR in Diagnostics

PCR is the cornerstone of molecular diagnostics. Applications include:

• Infectious Disease Detection: COVID-19 (RT-PCR for SARS-CoV-2 RNA), HIV (viral load monitoring), Hepatitis B/C (viral DNA/RNA detection), Tuberculosis (Mycobacterium tuberculosis DNA), Malaria (Plasmodium DNA)
• Genetic Disorder Screening: Cystic fibrosis (CFTR mutations), Sickle cell disease (HbS mutation), Thalassemia (β-globin mutations), Huntington's disease (CAG repeat expansion)
• Cancer Diagnostics: Detection of oncogenic mutations (EGFR, KRAS, BRAF), minimal residual disease monitoring, liquid biopsy (circulating tumor DNA)
• Prenatal Diagnosis: Non-invasive prenatal testing (NIPT) using fetal DNA circulating in maternal blood
• Pharmacogenomics: Detection of genetic variants affecting drug metabolism (CYP450 polymorphisms) to guide drug selection and dosing

ELISA (Enzyme-Linked Immunosorbent Assay)

ELISA is a plate-based assay designed for detecting and quantifying specific antigens or antibodies in a sample. It combines the specificity of antibodies with the sensitivity of enzyme-based detection.

Principle: An enzyme (usually horseradish peroxidase HRP or alkaline phosphatase AP) is conjugated to an antibody. When a chromogenic substrate is added, the enzyme catalyzes a color change reaction, which can be measured spectrophotometrically.

Types of ELISA:

• Direct ELISA: Antigen is immobilized on the plate, and an enzyme-conjugated primary antibody binds directly. Simple but less specific.
• Indirect ELISA: Antigen is immobilized, primary antibody binds, then enzyme-conjugated secondary antibody binds. More sensitive (signal amplification).
• Sandwich ELISA: Capture antibody is immobilized on the plate, antigen binds, then detection antibody (enzyme-conjugated) binds. Requires two antibodies recognizing different epitopes. Highly specific and sensitive.
• Competitive ELISA: Used for small antigens with only one epitope. Sample antigen competes with labeled antigen for antibody binding.

Clinical applications of ELISA:

• HIV Testing: ELISA detects anti-HIV antibodies in blood (screening test). Positive results are confirmed by Western blot.
• Hepatitis B Surface Antigen (HBsAg): Detects active HBV infection
• Pregnancy Testing: Detects human chorionic gonadotropin (hCG) in urine or blood
• Autoimmune Disease Diagnosis: Anti-nuclear antibodies (ANA) for SLE, anti-CCP for rheumatoid arthritis
• Food Allergen Detection: Detect peanut, gluten, milk proteins in processed foods
• Hormone Quantification: Thyroid hormones (TSH, T3, T4), cortisol, insulin

Other molecular diagnostic techniques:

• Southern Blotting: Detects specific DNA sequences. DNA is digested with RE, separated by electrophoresis, transferred to a membrane, and probed with labeled complementary DNA.
• Northern Blotting: Similar but for RNA (detects gene expression levels).
• Western Blotting: Uses antibodies to detect specific proteins after gel electrophoresis and membrane transfer.
• DNA Microarrays: Thousands of DNA probes on a chip for simultaneous analysis of gene expression or genotyping.
• FISH (Fluorescence In Situ Hybridization): Fluorescent probes bind to specific chromosomal regions for detecting deletions, translocations, or aneuploidies.

5. Applications in Agriculture

Genetically Modified Crops

Genetically Modified (GM) crops are plants whose genomes have been altered through genetic engineering techniques to introduce desirable traits. These traits include pest resistance, herbicide tolerance, enhanced nutritional value, improved shelf life, and abiotic stress tolerance (drought, salinity, cold).

Global adoption: In 2023, GM crops were cultivated on over 190 million hectares in 29 countries, with the United States, Brazil, Argentina, India, and Canada being the largest producers. The major GM crops include soybean (50% of global area), maize (30%), cotton (15%), and canola (5%).

Bt Cotton

Bt cotton is a genetically modified cotton variety that produces insecticidal proteins from the bacterium Bacillus thuringiensis. This makes the plant resistant to certain insect pests, particularly bollworms (Lepidoptera larvae).

Mechanism of Bt toxin action:

1. The cry (crystal) gene from Bacillus thuringiensis is inserted into the cotton genome
2. The plant produces Cry proteins (e.g., Cry1Ac, Cry1Ab, Cry2Ab) as inactive protoxins
3. When an insect larva feeds on the plant, the protoxin is ingested and reaches the insect's midgut
4. The alkaline pH (7.5-10.5) of the insect midgut activates the protoxin by proteolytic cleavage
5. The activated toxin binds to specific receptors (cadherin-like proteins, aminopeptidase N, alkaline phosphatase) on the midgut epithelial cell membrane
6. The toxin inserts into the membrane, forming ion channels/pores
7. This disrupts the membrane potential, causes osmotic lysis of midgut cells, and leads to rapid death of the insect larva within 24-48 hours

Why Bt toxin is safe for humans:

• Human gut is acidic (pH 1.5-3.5), which does not activate the Cry protoxin
• Humans lack the specific receptors found in insect midgut cells
• The toxin is rapidly degraded in the human digestive system
• Bt toxins are highly specific to certain insect orders (Cry1 → Lepidoptera, Cry3 → Coleoptera, Cry2 → Lepidoptera and Diptera)

Bt cotton in India:

• Approval: Approved for commercial cultivation in 2002 by the Genetic Engineering Approval Committee (GEAC)
• Impact: Reduced insecticide use by ~50%, increased cotton yield by ~30-40%, and improved farmer incomes
• Varieties: Bollgard I (Cry1Ac single gene, 2002), Bollgard II (Cry1Ac + Cry2Ab stacked genes, 2006)
• Adoption: Over 95% of Indian cotton area is now under Bt cotton
• Controversies: Concerns about seed cost, pest resistance development (pink bollworm resistance reported in 2014), and impact on biodiversity

Other Bt crops: Bt corn (European corn borer resistance), Bt brinjal (eggplant, fruit and shoot borer resistance, approved in Bangladesh but not India), Bt soybean, Bt potato (Colorado beetle resistance).

Golden Rice

Golden Rice is a genetically modified rice variety engineered to produce β-carotene (pro-vitamin A) in the grain endosperm. It was developed to address vitamin A deficiency (VAD), which affects ~250 million children worldwide and causes blindness, weakened immunity, and increased mortality.

Genetic modifications involved:

• First generation (Golden Rice 1, 2000):
  • psy gene from daffodil (Narcissus pseudonarcissus) encodes phytoene synthase
  • crtI gene from soil bacterium Erwinia uredovora encodes phytoene desaturase
  • Both genes were placed under endosperm-specific promoters
  • Result: Rice grains produced 1.6 μg/g β-carotene (insufficient for dietary needs)
• Second generation (Golden Rice 2, 2005):
  • The daffodil psy gene was replaced with the maize psy gene
  • Result: Rice grains produced up to 37 μg/g β-carotene (sufficient to meet dietary requirements)

Regulatory status: Golden Rice has been approved for human consumption in Australia, New Zealand, Canada, the Philippines, and the United States. It has faced significant regulatory hurdles and opposition from anti-GMO groups, delaying its deployment for nearly two decades.

Other nutritionally enhanced GM crops:

• Biofortified Sorghum: Enhanced with β-carotene, iron, and zinc
• High-Oleic Soybean: Increased monounsaturated fat (oleic acid), reduced trans fats
• Iron-Fortified Rice: Increased iron content through overexpression of ferritin (from soybean) and enhanced iron uptake by overproducing nicotianamine synthase
• Low-Allergen Peanut: Silencing of major allergen genes (Ara h 1, Ara h 2)

RNAi Technology

RNA interference (RNAi) is a natural cellular mechanism for post-transcriptional gene silencing. Double-stranded RNA (dsRNA) triggers the degradation of complementary mRNA molecules, preventing protein production.

Mechanism of RNAi:

1. dsRNA (either introduced experimentally or produced from a hairpin RNA construct) is recognized by the enzyme Dicer (an RNase III endonuclease)
2. Dicer cleaves dsRNA into short fragments called siRNAs (small interfering RNAs, 21-23 nucleotides long)
3. siRNAs are loaded into the RISC (RNA-Induced Silencing Complex)
4. The siRNA is unwound, and the guide strand (complementary to the target mRNA) remains in RISC
5. RISC uses the guide siRNA to find and bind complementary mRNA sequences
6. Argonaute (Ago2), the catalytic component of RISC, cleaves the target mRNA
7. The cleaved mRNA is degraded, silencing the gene

Applications of RNAi in agriculture:

• Virus Resistance: Papaya resistant to ringspot virus (PRSV) was developed by inserting the viral coat protein gene into the plant genome. This triggers RNAi against the viral RNA, providing resistance. This is one of the most successful examples of RNAi-based crop protection.
• Nematode Resistance: In tobacco, RNAi was used to target a root-knot nematode (Meloidogyne incognita) gene. The plant expresses dsRNA complementary to an essential nematode gene. When the nematode feeds on the plant roots, it ingests the dsRNA, triggering RNAi in the nematode and killing it.
• Fruit Ripening Control: The Flavr Savr tomato (Calgene, 1994) used antisense RNA against the polygalacturonase (PG) gene. PG degrades pectin in the cell wall during ripening. Silencing PG delays softening, allowing tomatoes to ripen on the vine without becoming too soft for shipping.
• Insect Resistance: RNAi against insect CYP450 genes (involved in detoxification) can increase insect susceptibility to pesticides.
• Reduction of Plant Allergens: RNAi silencing of allergen genes in soybean (Gly m Bd 30K), wheat, and peanut.

RNAi in medicine:

• Patisiran (Onpattro, 2018): First FDA-approved siRNA drug. Targets transthyretin (TTR) mRNA for treatment of hereditary transthyretin-mediated amyloidosis.
• Givosiran (Givlaari, 2019): siRNA targeting ALAS1 for acute hepatic porphyria.
• Inclisiran (Leqvio, 2020): siRNA targeting PCSK9 for lowering LDL cholesterol.

6. Transgenic Animals

Uses & Examples

Transgenic animals are animals that have had foreign genes deliberately inserted into their genome. These animals are used for various scientific, medical, and agricultural purposes.

Methods for creating transgenic animals:

• Pronuclear Microinjection: The foreign DNA is injected directly into the pronucleus of a fertilized egg using a fine glass needle. The egg is then implanted into a surrogate mother. This is the most common method for creating transgenic mice.
• Embryonic Stem (ES) Cell Method: Foreign DNA is introduced into ES cells (from the inner cell mass of early embryos), which are then injected into a host blastocyst. The resulting chimeric animal carries the transgene in some of its tissues.
• Somatic Cell Nuclear Transfer (Cloning): A somatic cell is genetically modified, and its nucleus is transferred to an enucleated egg. This was the method used to create Dolly the sheep.
• Retroviral Vectors: A retrovirus carrying the foreign gene infects early embryos or ES cells, integrating the gene into the host genome.
• CRISPR-Cas9: The most recent and efficient method for creating targeted genetic modifications. Allows precise gene insertion, deletion, or replacement.

Applications of transgenic animals:

Application	Description	Examples
Disease Models	Animals carrying human disease genes to study pathology and test therapies	OncoMouse (cancer), Alzheimer's mice (APP/PS1 mutations), Parkinson's models (α-synuclein), Cystic Fibrosis mice (CFTR knockout)
Pharming (Biopharmaceuticals)	Animals producing therapeutic human proteins in milk, urine, eggs, or blood	Rosie cow (α-lactalbumin-enriched milk), Tracy sheep (α-1-antitrypsin in milk), Goats produced antithrombin (ATryn)
Xenotransplantation	Genetically modified pigs with cells/tissues that do not trigger hyperacute rejection in humans	GGTA1-knockout pigs (no α-Gal epitope), human complement regulatory protein (CD46, CD55) transgenic pigs
Functional Genomics	Understanding gene function by observing effects of specific gene modifications	Knockout mice (gene function), Knockin mice (humanized genes), Conditional knockout (Cre-loxP system)
Improving Animal Production	Cattle, sheep, goats, pigs, and fish with enhanced growth, disease resistance, or product quality	Growth hormone transgenic salmon (AquAdvantage, fast-growing), PRRSV-resistant pigs (CD163 knockout)
Toxicity Testing	Animals engineered to be sensitive to specific toxins for drug safety and environmental testing	Transgenic mice with human drug metabolism genes (CYP450) for more relevant toxicity tests

Notable transgenic animal milestones:

• Dolly the Sheep (1996): First mammal cloned from an adult somatic cell using somatic cell nuclear transfer (SCNT). Created by Ian Wilmut and colleagues at the Roslin Institute, Scotland. Dolly lived for 6 years and gave birth to several lambs. She had shortened telomeres, indicating premature aging.
• OncoMouse (1984): First transgenic mouse carrying an activated oncogene (c-myc). Highly susceptible to cancer. Patented by Harvard University (first patent for a transgenic animal).
• Knockout Mice (1989): First gene-targeted (knockout) mice created using homologous recombination in ES cells. This led to the Nobel Prize in 2007 for Capecchi, Evans, and Smithies.
• AquAdvantage Salmon (2015): First genetically modified animal approved for human consumption. Contains Chinook salmon growth hormone gene and ocean pout antifreeze protein gene promoter. Grows to market size in half the time of conventional salmon.

7. Biosafety & Ethical Issues

GM Debate

The debate over genetically modified organisms (GMOs) involves scientific, ethical, economic, and social considerations. Both proponents and opponents raise valid concerns that must be carefully evaluated.

Arguments in favor of GMOs:

• Increased Crop Yields: GM crops often produce higher yields per hectare, which is essential for feeding a growing global population (expected to reach 9.7 billion by 2050).
• Reduced Pesticide Use: Bt crops have significantly reduced the use of chemical insecticides. In India, insecticide use on cotton decreased by ~50% after Bt cotton adoption.
• Enhanced Nutritional Value: Golden Rice addresses vitamin A deficiency; biofortified crops can combat malnutrition in developing countries.
• Environmental Benefits: Herbicide-tolerant crops enable no-till farming, reducing soil erosion and CO₂ emissions.
• Drought and Salt Tolerance: GM crops that tolerate abiotic stresses could maintain food production under climate change conditions.
• Reduced Food Waste: Delayed ripening (Flavr Savr tomato) and longer shelf life reduce post-harvest losses.

Arguments against GMOs:

• Environmental Risks:
  • Gene Flow: Transgenes can spread to wild relatives through cross-pollination, potentially creating "superweeds" (herbicide-resistant weeds) or disrupting natural ecosystems.
  • Loss of Biodiversity: Monoculture of GM crops reduces genetic diversity in cultivated species. Bt crops might affect non-target organisms (e.g., monarch butterfly larvae affected by Bt corn pollen in laboratory studies, though field effects are minimal).
  • Pesticide Resistance: Continuous exposure to Bt crops selects for resistant insect populations. Pink bollworm resistance to Bt cotton has been reported in India (2014).
• Health Risks:
  • Allergenicity: The introduced gene might encode an allergenic protein. Rigorous testing is required to assess this risk.
  • Antibiotic Resistance Markers: Use of antibiotic resistance genes as selectable markers could theoretically transfer to pathogens, but the risk is extremely low.
  • Unintended Effects: Insertion of a transgene might disrupt host genes or affect metabolic pathways, potentially producing unexpected compounds.
• Socioeconomic Concerns:
  • Corporate Control: A few multinational corporations (Monsanto-Bayer, Syngenta-ChemChina, Corteva) control most GM seed patents, raising concerns about farmer dependence, seed pricing, and monopolistic practices.
  • Small Farmer Impact: High seed costs and restrictive intellectual property rights can burden small and marginal farmers.
• Ethical Concerns: "Playing God" argument — crossing species barriers is seen as unnatural by some. Religious concerns about consuming transgenic food (e.g., pig genes in plants).

Biopiracy

Biopiracy refers to the commercial exploitation of biological resources (genes, species, traditional knowledge) by multinational corporations or developed countries without fair compensation to the countries and communities from which they were obtained. It is a major concern for biodiversity-rich developing countries like India.

Notable cases of biopiracy:

• Basmati Rice (1997): The US-based company RiceTec was granted a US patent for "Basmati rice lines and grains" (Patent #5,663,484). The patent covered varieties derived from Indian Basmati. India challenged the patent, and RiceTec withdrew several claims. Most claims were cancelled, but some were allowed as narrow claims (not covering Indian Basmati).
• Turmeric (1995): Two US scientists were granted a US patent (Patent #5,401,504) for "use of turmeric in wound healing." The Indian Council of Scientific and Industrial Research (CSIR) challenged the patent, providing evidence from ancient Sanskrit texts and traditional knowledge. The US Patent and Trademark Office (USPTO) revoked the patent in 1997.
• Neem (1994): The US company W.R. Grace and the US Department of Agriculture were granted a European patent (EP0436257) for "a method for controlling fungi on plants using neem oil formulation." The patent was challenged by a coalition of groups including Dr. Vandana Shiva and the Indian government. The European Patent Office (EPO) ruled against the patent in 2000 (confirmed on appeal in 2005) because neem's antifungal properties were part of traditional Indian knowledge.
• Karela (Bitter Melon): A patent was filed in the US on the use of karela, jamun, and brinjal for diabetes treatment. Based on traditional Indian medicine knowledge.
• Amaranth (1994): A US patent was granted on a Mexican amaranth variety with high protein content. After opposition, the patent was narrowed.

Mechanisms to prevent biopiracy:

• Cartagena Protocol on Biosafety (2000): An international treaty under the UN Convention on Biological Diversity (CBD) that regulates the safe transfer, handling, and use of GMOs. Establishes the Advance Informed Agreement (AIA) procedure.
• Nagoya Protocol (2010): International agreement on access to genetic resources and fair and equitable sharing of benefits arising from their utilization.
• Traditional Knowledge Digital Library (TKDL) in India: A database of traditional Indian medicinal knowledge (Ayurveda, Unani, Siddha, Yoga) in multiple languages. Used to prevent patent offices from granting patents on existing traditional knowledge.
• India's Biological Diversity Act (2002): Regulates access to biological resources and associated knowledge, with provisions for benefit sharing.

Patents

Patent is an exclusive right granted by the government to an inventor to prevent others from making, using, or selling the invention for a limited period (usually 20 years). In biotechnology, patenting raises significant ethical and legal questions.

What can be patented in biotechnology?

• Genes and DNA sequences: Isolated and purified genes with a known function can be patented in many countries (US, EU, Japan). This has been controversial — the "Myriad Genetics" case (BRCA1/BRCA2 gene patents for breast cancer) was challenged in the US Supreme Court (2013), which ruled that naturally occurring DNA sequences cannot be patented. However, complementary DNA (cDNA) can be patented because it is not naturally occurring.
• Recombinant Proteins: Genetically engineered therapeutic proteins (insulin, growth hormone, erythropoietin) can be patented.
• Genetically Modified Organisms: Transgenic animals, plants, and microbes can be patented. The Harvard OncoMouse was the first transgenic animal patent (US Patent #4,736,866, 1988). In Europe, the patent was initially rejected due to ethical concerns but eventually granted with limitations.
• Processes and Methods: PCR (patented by Cetus Corporation), recombinant DNA technology methods, and gene therapy delivery methods.

Indian Patent Act (1970, amended 2005):

• Section 3(a): Frivolous inventions or inventions contrary to law or morality cannot be patented
• Section 3(b): Plants and animals (including seeds, varieties, and biological processes for their production) cannot be patented
• Section 3(c): Mathematical methods, business methods, and computer programs per se cannot be patented
• Section 3(d): Key provision — New forms of a known substance (salts, esters, ethers, polymorphs, metabolites, pure forms, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives) are not considered patentable unless they show significantly enhanced efficacy. This was specifically designed to prevent "evergreening" of patents.
• Section 3(e): Mere admixture of known substances without synergistic effect cannot be patented
• Section 3(i): Plants and animals in whole or any part cannot be patented
• Section 5: Only process patents are allowed for pharmaceutical substances (not product patents). This was amended in 2005 to allow product patents, complying with WTO TRIPS agreement requirements.

Landmark case: Novartis Glivec (Imatinib Mesylate)

• Drug: Imatinib mesylate (Glivec/Gleevec) — a tyrosine kinase inhibitor used for treating chronic myeloid leukemia (CML)
• Issue: Novartis filed a patent application in India for the beta-crystalline form of imatinib mesylate (2006), claiming it was a new invention with enhanced efficacy
• Opposition: The patent was opposed by the Indian generic drug industry and patient advocacy groups. They argued that:
  • The beta-crystalline form was not a new substance but merely a new form of the known salt (imatinib mesylate)
  • Novartis had not demonstrated significantly enhanced efficacy under Section 3(d)
  • The drug was already known and patented in the US and other countries
• Judgment (2013): The Supreme Court of India rejected Novartis' patent application, upholding Section 3(d). The Court ruled that the beta-crystalline form of imatinib mesylate did not show significantly enhanced therapeutic efficacy over the known form. The verdict was a landmark for access to affordable medicines in developing countries.

Regulatory bodies for biotechnology in India:

Regulatory Body	Function
RCGM (Review Committee on Genetic Manipulation)	Monitors ongoing rDNA research activities and approves small-scale field trials of GM crops
GEAC (Genetic Engineering Appraisal Committee)	Under the Ministry of Environment, Forest and Climate Change. Approves large-scale field trials and commercial release of GMOs. Is the apex regulatory body.
IBSC (Institutional Biosafety Committee)	Operates at the institutional level. Reviews and approves rDNA research proposals. Enforces biosafety guidelines.
DBT (Department of Biotechnology)	Ministry of S&T. Coordinates and promotes biotechnology research, education, and commercialization in India.
FSSAI (Food Safety and Standards Authority of India)	Regulates GM foods and their labeling for safety assessment and consumer information.

Summary & Quick Revision

Topic	Key Points
Restriction Enzymes	Type II used in rDNA; palindromic sites; produce sticky/blunt ends; EcoRI (GAATTC), HindIII (AAGCTT)
Cloning Vectors	ori (replication), selectable marker (antibiotic resistance), MCS (polylinker), small size; pBR322 (4361 bp), BAC (100-300 kb), YAC (200-2000 kb)
PCR	Kary Mullis; Denaturation 94°C, Annealing 50-65°C, Extension 72°C; Taq polymerase from T. aquaticus
rDNA Steps	Isolate DNA → Cut with RE → Ligate → Transform → Screen → Express
Blue-White Screening	Blue = no insert (functional lacZ); White = insert present (disrupted lacZ)
Recombinant Insulin	Humulin (1982, Eli Lilly); A + B chains produced separately, then joined
Bt Cotton	Cry gene (B. thuringiensis); Cry protein → activated in insect alkaline gut → pore formation → insect death
Golden Rice	β-carotene (pro-vitamin A) in endosperm; psy gene (daffodil/maize) + crtI gene (Erwinia)
RNAi	dsRNA → Dicer → siRNA → RISC → mRNA cleavage; used in Flavr Savr tomato, virus-resistant papaya
Gene Therapy	SCID (ADA deficiency, 1990); Ex vivo & In vivo; Viral vectors (retrovirus, AAV, lentivirus)
ELISA	Detects antigen/antibody; enzyme (HRP/AP) + chromogenic substrate; HIV screening, pregnancy test
Biopiracy	Basmati (RiceTec, 1997), Turmeric (CSIR challenged, 1997), Neem (EPO revoked, 2005)
Indian Patent Act	Section 3(d): no patent for new forms without enhanced efficacy; Novartis Glivec case (2013)
Regulatory Bodies	GEAC (approves GMOs), RCGM (rDNA research), IBSC (institutional level)